The founder mutation MSH2*1906G-->C is an important cause of hereditary nonpolyposis colorectal cancer in the Ashkenazi Jewish population.
about
Review of the Lynch syndrome: history, molecular genetics, screening, differential diagnosis, and medicolegal ramificationsHow old is this mutation? - a study of three Ashkenazi Jewish founder mutations.Defective mismatch repair, microsatellite mutation bias, and variability in clinical cancer phenotypesSome aspects of molecular diagnostics in Lynch syndrome.Racial differences in MLH1 and MSH2 mutation: an analysis of yellow race and white race based on the InSiGHT database.Molecular analysis of hereditary nonpolyposis colorectal cancer in the United States: high mutation detection rate among clinically selected families and characterization of an American founder genomic deletion of the MSH2 gene.Genomewide linkage scan for schizophrenia susceptibility loci among Ashkenazi Jewish families shows evidence of linkage on chromosome 10q22.MSH2 c.1452-1455delAATG is a founder mutation and an important cause of hereditary nonpolyposis colorectal cancer in the southern Chinese population.Replication of an association of a common variant in the Reelin gene (RELN) with schizophrenia in Ashkenazi Jewish women.Genomewide linkage scan for bipolar-disorder susceptibility loci among Ashkenazi Jewish familiesThe mutational spectrum of Lynch syndrome in cyprus.Application of molecular diagnostics for the detection of Lynch syndrome.Current clinical criteria for Lynch syndrome are not sensitive enough to identify MSH6 mutation carriers.Report of a Novel Mutation in MLH1 Gene in a Hispanic Family from Puerto Rico Fulfilling Classic Amsterdam Criteria for Lynch SyndromeFunctional variants in DPYSL2 sequence increase risk of schizophrenia and suggest a link to mTOR signalingHereditary ovarian carcinoma: heterogeneity, molecular genetics, pathology, and management.An American founder mutation in MLH1.Cancer in Jews: introduction and overview.Genetic factors and colorectal cancer in Ashkenazi Jews.Characterization of two Ashkenazi Jewish founder mutations in MSH6 gene causing Lynch syndromeThe New York Cancer Project: rationale, organization, design, and baseline characteristicsPhenotypic and genotypic heterogeneity in the Lynch syndrome: diagnostic, surveillance and management implications.A multifactorial likelihood model for MMR gene variant classification incorporating probabilities based on sequence bioinformatics and tumor characteristics: a report from the Colon Cancer Family Registry.A unique MSH2 exon 8 deletion accounts for a major portion of all mismatch repair gene mutations in Lynch syndrome families of Sardinian origin.GREM1 germline mutation screening in Ashkenazi Jewish patients with familial colorectal cancerIdentification of a prostate cancer susceptibility locus on chromosome 7q11-21 in Jewish families.High risk of colorectal and endometrial cancer in Ashkenazi families with the MSH2 A636P founder mutation.Tumor spectrum in lynch syndrome, DNA mismatch repair system and endogenous carcinogens.Mismatch repair genes founder mutations and cancer susceptibility in Lynch syndrome.Single-amplicon MSH2 A636P mutation testing in Ashkenazi Jewish patients with colorectal cancer: role in presurgical management.Common MUTYH mutations and colorectal cancer risk in multiethnic populations.The MLH1 D132H variant is associated with susceptibility to sporadic colorectal cancer.Haplotype analysis suggest that the MLH1 c.2059C > T mutation is a Swedish founder mutation.MSH2 Loss in Primary Prostate Cancer.Constitutional Mismatch Repair Deficiency in Israel: High Proportion of Founder Mutations in MMR Genes and Consanguinity.Recent progress in Lynch syndrome and other familial colorectal cancer syndromes.Linkage and association on 8p21.2-p21.1 in schizophrenia.A founder MLH1 mutation in Lynch syndrome families from Piedmont, Italy, is associated with an increased risk of pancreatic tumours and diverse immunohistochemical patterns.A prospective study of the clinical, genetic, screening, and pathologic features of a family with hereditary mixed polyposis syndrome.Genetic analyses in consecutive israeli jewish colorectal cancer patients.
P2860
Q24610838-4E6D24A0-B9AD-4C43-B0B0-73C64E9F6077Q33578304-F7F631A6-B11A-41B9-BDF3-215E6211E18AQ33596701-0319587E-E956-4DBF-83FA-5F1AA6D61296Q33722604-B21C7937-CEE7-4C8A-AE47-8291859CEAD6Q33770899-D2C23F42-63A5-40B5-B0A9-7D2DE104E4D5Q33904639-7DC076E6-E3CD-4275-B432-6B26A2FD4536Q33906350-7F50DE96-DE3C-4763-BA4A-92BE1A2F2336Q33909800-A9A8A27C-AD81-4FAD-B01A-036FB6B9F881Q33984019-1B59865E-1469-4AEA-8A6C-AFFD42928656Q33998507-6D498A1D-B481-4CBF-BACA-838E3A4D1DD3Q34062115-08F4B5BB-FA64-43F9-A6E0-5515FEA1DC7AQ34088809-2D3BD234-1246-403E-9C68-57C5BBD7B23AQ34289520-1994676E-3239-41C9-BA3A-1CB084295702Q34441648-5FE40DA4-25AA-4BE1-A9D9-1DEF0D7B29C1Q34923904-2EA3B380-CAB5-42DD-B608-43B629C523A9Q34977063-13D1A89F-4725-480F-913D-25BFC8B13930Q35700015-E37CC9D8-AD29-4C55-9BCC-88465C767874Q35934020-349C54F1-9791-4269-9CB8-F383CE122A25Q35934035-1DA75775-6EB4-4396-BBCC-5A2BA92160F3Q35971538-6FE187CF-E1F5-4F6B-BA44-64DE64A3959FQ36274137-4DC553DB-E7ED-451D-BFFC-993DCDE52C1AQ36396727-3E48C4AF-C71E-4E9F-A4BD-016AD0D0419CQ36512734-74EB3F61-5EBA-47FC-9B33-DA39B0CB289BQ36543031-DCBE383C-3C3B-45B5-A26A-1ABDFD95F8FAQ36555751-78506A3F-6C83-44F5-9E73-C1F4C7989607Q36604157-CD006871-5137-450A-B1A9-D0A6D052F17BQ36808349-EF5F4FF6-8D97-4BD5-8ED8-DDE012D5C7DAQ37978580-954A2871-8579-4640-99CF-07CBB5E5B522Q38262826-B02E4953-7D55-4FE1-91F7-0C3729193716Q42616545-E89154B3-E0F0-44EF-BD81-F2FF58313701Q44681647-8C0F625E-5333-4C4D-AF8B-224AA6F56732Q46118451-C3852D16-657A-415B-87B0-30176C53F117Q47177393-D1D2C487-2ECE-4996-A546-ED95C79FD819Q47976701-F388998D-6EAC-491B-B711-FE91E816DA44Q52147073-32760DFC-EACE-4E1B-971A-F6A7A943AD4CQ53081522-6ACA1EB8-14C7-4D0A-BE11-E0154EA132CAQ53159308-C30E5159-F266-48BE-82AA-31DC747811FBQ54210037-F07F29C8-876F-4C1A-A7B7-0B7CBE6BC76EQ54516679-50B92D03-4CE4-4178-9F77-3F7A15091373Q54661237-40B21645-1377-460B-9F2A-2F41F68F0EC6
P2860
The founder mutation MSH2*1906G-->C is an important cause of hereditary nonpolyposis colorectal cancer in the Ashkenazi Jewish population.
description
2002 nî lūn-bûn
@nan
2002 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած
@hyw
2002 թվականի նոյեմբերին հրատարակված գիտական հոդված
@hy
2002年の論文
@ja
2002年論文
@yue
2002年論文
@zh-hant
2002年論文
@zh-hk
2002年論文
@zh-mo
2002年論文
@zh-tw
2002年论文
@wuu
name
The founder mutation MSH2*1906 ...... e Ashkenazi Jewish population.
@ast
The founder mutation MSH2*1906 ...... e Ashkenazi Jewish population.
@en
The founder mutation MSH2*1906 ...... e Ashkenazi Jewish population.
@nl
type
label
The founder mutation MSH2*1906 ...... e Ashkenazi Jewish population.
@ast
The founder mutation MSH2*1906 ...... e Ashkenazi Jewish population.
@en
The founder mutation MSH2*1906 ...... e Ashkenazi Jewish population.
@nl
prefLabel
The founder mutation MSH2*1906 ...... e Ashkenazi Jewish population.
@ast
The founder mutation MSH2*1906 ...... e Ashkenazi Jewish population.
@en
The founder mutation MSH2*1906 ...... e Ashkenazi Jewish population.
@nl
P2093
P2860
P50
P356
P1476
The founder mutation MSH2*1906 ...... e Ashkenazi Jewish population.
@en
P2093
A De La Chapelle
A Markowitz
B Bressac-De Paillerets
C M T Greenwood
E Friedman
E MacNamara
P2860
P304
P356
10.1086/345075
P407
P577
2002-11-26T00:00:00Z